14-day Premium Trial Subscription Try For FreeTry Free
NASDAQ:CNAT
Delisted

Conatus Pharmaceuticals Inc. Stock Price (Quote)

$0.255
+0 (+0%)
At Close: May 27, 2022

Range Low Price High Price Comment
30 days $0.255 $0.255 Friday, 27th May 2022 CNAT stock ended at $0.255. During the day the stock fluctuated 0% from a day low at $0.255 to a day high of $0.255.
90 days $0.238 $0.275
52 weeks $0.203 $1.23

Historical Conatus Pharmaceuticals Inc. prices

Date Open High Low Close Volume
Jul 15, 2019 $0.334 $0.355 $0.320 $0.325 1 204 938
Jul 12, 2019 $0.423 $0.430 $0.334 $0.342 3 255 611
Jul 11, 2019 $0.325 $0.465 $0.313 $0.450 6 900 525
Jul 10, 2019 $0.314 $0.337 $0.300 $0.325 1 362 554
Jul 09, 2019 $0.299 $0.319 $0.290 $0.309 640 619
Jul 08, 2019 $0.318 $0.319 $0.280 $0.300 1 180 205
Jul 05, 2019 $0.329 $0.329 $0.300 $0.307 1 096 286
Jul 03, 2019 $0.280 $0.343 $0.273 $0.330 2 767 448
Jul 02, 2019 $0.295 $0.295 $0.263 $0.287 858 159
Jul 01, 2019 $0.280 $0.290 $0.262 $0.270 1 116 527
Jun 28, 2019 $0.270 $0.289 $0.260 $0.260 1 661 215
Jun 27, 2019 $0.272 $0.330 $0.250 $0.290 5 043 939
Jun 26, 2019 $0.300 $0.320 $0.281 $0.283 3 229 695
Jun 25, 2019 $0.350 $0.395 $0.280 $0.290 9 181 060
Jun 24, 2019 $0.93 $0.95 $0.86 $0.92 1 179 727
Jun 21, 2019 $0.98 $0.98 $0.91 $0.92 261 595
Jun 20, 2019 $1.02 $1.03 $0.98 $1.00 430 161
Jun 19, 2019 $0.93 $1.07 $0.83 $0.99 1 142 960
Jun 18, 2019 $0.735 $1.03 $0.727 $0.94 1 611 435
Jun 17, 2019 $0.778 $0.780 $0.710 $0.712 306 952
Jun 14, 2019 $0.762 $0.778 $0.720 $0.770 121 098
Jun 13, 2019 $0.720 $0.780 $0.720 $0.762 137 418
Jun 12, 2019 $0.80 $0.80 $0.720 $0.730 192 810
Jun 11, 2019 $0.770 $0.770 $0.733 $0.747 86 033
Jun 10, 2019 $0.750 $0.780 $0.732 $0.760 113 196
Click to get the best stock tips daily for free!

About Conatus Pharmaceuticals Inc.

Conatus Pharmaceuticals. Conatus Pharmaceuticals Inc., a biotechnology company, focuses on the development and commercialization of novel medicines to treat liver diseases in the United States. Its product candidates include Emricasan, an orally active pan-caspase protease inhibitor that is in Phase II clinical trials for the treatment of liver cirrhosis, acute-on-chronic liver failure, post-orthotopic liver transplant as a result of hepatitis C virus infection with sust... CNAT Profile

Top Fintech Company

StockInvest.us featured in The Global Fintech Index 2020 as the top Fintech company of the country.

Full report by FINDEXABLE

ROCKIT